启明医疗-B2024年度报告

2467526294126131133135136139257 1 2 3 2024 TAVR TAVR20244.778.1%112.6%9,77020.7% 20248,250202313.5%202314.8%17.5%VenusP-Valve20241370 •Venus-PowerXTAVRVenus-VitaeTAVR•Cardiovalve120 •VenusP-ValveIDEVenusP-Valve 20242025312 20252025 I. TAVRTPVRTMVRTTVR TAVRVenus-PowerXTAVRVenus-VitaeVenusP-ValveCardiovalve 9.3%20.7%TAVR650VenusP-ValveVenusP-Valve82.513.5%17.5%1360 TAVR– VenusA-ValveVenusA-Plus VenusA-ProVenusA-DeluxeTPVRVenusP-ValveG SheathTAV0TAVRVenus-PowerXVenus-VitaeTMVRTTVRCardiovalveTPVRVenusP-Valve VenusATAVR TAVRVenusA-ValveVenusA-Plus VenusA-ProVenus-DeluxeVenusA-ValveNMPANMPATAVRVenusA-PlusNMPATAVR VenusA-ProNMPAVenusA-PlusVenusA-DeluxeNMPATAVRVenusA-Deluxe VenusA-ValveTAVRCSC2024VenusA-ValveTAVR20%12VenusA-Valve10China ValveHangzhou2024VenusA-Plus43VenusA-PlusVenusA-Plus VenusP-ValveTPVR (TPVR)VenusP-ValveCE MDR(RVOT)TPVRCE MDRIIIVenusP-ValveNMPATPVR VenusP-ValvePICSVenusP-Valve50VenusP-Valve6MRI51(1.3%)2≥0≥0594%NYHA I/II18VenusP-Valve118VenusP-Valve VenusP-ValveIDE (PROTEUS)60Centers for Medicare & Medicaid Services, CMSCMSVenusP-Valve Venus-PowerXTAVR TAVRVenus-PowerX Venus-PowerXVenus-EnduraSeadapt100%100%3VVenus-PowerXVenus-PowerX Venus-PowerX Venus-VitaeTAVR TAVRVenus-Vitae Venus-VitaeVenus-EnduraSeadaptVenus-VitaeVenus-Vitae Venus-Vitae CardiovalveTMVR/TTVR CardiovalveCardiovalve Cardiovalve55mm95%Cardiovalve CardiovalveTarget CE301202024London Valves 2024Target CE10593.7%CSI 2024Cardiovalve20100%3090%CardiovalveCardiovalve Cardiovalve TAVRVenus-VitaeVenus-PowerXVenusP-ValveIDECardiovalve 341.2524.9 886473402275460435PCT24 20202023 3,500GMP ISO13485NMPAGMPFDAQSRMDRANVISARDCMDSAP ISO/IEC17025ISO13485MDRMDSAPBGMPCNASPLMEBSWMSLIMSMESECS 20249.3%20.7% 650901005,500200TAVRTPVR 82.5202313.5%601324EuroPCR 2024, CSI2024PICS2024PCR London Valves 2024PICS2024VenusP-Valve II. VenusA-ValveVenusA-ValveVenusP-ValveCE MDRNMPA 470.8491.44.2%TAVR 103.1102.20.9% 389.25.5%367.779.2%78.1% 38.5241.684.1% 245.1300.518.4% 341.2524.935.0% 146.0153.85.1% 372.4314.018.6%Opus Medical Therapies, LLCOpus OpusTMVR/TTVROpusTMVRTTVR4.01.05.01.0OpusVivek Rajapopal40.7%OpusOpus Opus1OpusOpus2OpusOpus3Opus Opus9.0OpusOpus OpusOpus OpusOpus0.5OpusOpusOpus Opus2024Opus1OpusOpus2OpusOpus3OpusOpus Opus(1)Opus(2)Opus(3)Opus4OpusOpus Opus73.616.4 Liwen RF® NMPA Liwen RF® Liwen RF® (1)(2)(3)62.015.8 17 338.2464.2126.0 123456 21.42.223.6 16.662.773.5% 4.212.466.1% 23.36.3269.8% EBITDAEBITDA EBITDAEBITDA EBITDA 2 3EBITDA 298.0774.461.5% 283.0705.929 16.7%28.3% 440.7802.945.1% 5% 41.6(i)(ii) 265.5569.1 (i)(ii) 363.9MitraltechCardiovalve (i)Hangzhou Kuntai(ii)(iii)(iv)(v)(vi)(vii)(viii) Hangzhou Kuntai200,000,000 80,000,000 691865 69159695 III. 1.2.3.4. IV. (A)(i)(ii)(iii)(iv)(v)(vi)(B)(C)(D) • ••••• •••••• ••••••••TAVR ••••••• ••••••• •••• ••••• •••••••• •••••• ••••••••••• • • (i) (ii) (iii) (iv) • 10 • 51 20Transcatheter Technologies GmbHEndoCor Pte. Ltd.Embryon, Inc. 40 49CEMDR 4010China eCapital Corporation2216 42 Kohlberg Kravis Roberts & Co.L.P. 600867.SH600690.SHNYSE:CO221611463377 1146600867.SH (HKINED) 71 UFJ 140661515261614771105870011288270966SincereWatchHong Kong Limited444 Teesside Polytechnic 250,000 60 20 107312041748 6120 4016 41 36 60306554LDKCPCCSIQ I. ESG TAVRTPVR IV. 4.50200,000,000150Venus-PowerX 13.51B(1) (i) (i)3.10(1)(ii)3.10A(iii)3.21(iv)3.27A 3.10(1)3.10A 3.213.27A (ii) (iii) (iv) (a)(b) 9.10. 9.7.(i)(ii) II. 3.13 486 39.14A XV(a)XV78(b)352(c) (1)H441,011,443441,010,235H1,208 XV23336 (1)Horizon Binjiang LLC33,651,618HHorizon Binjiang LLC (2)32,720,498H10,569,132H1,208 •Adventure 03 Limited476,224HDinovaHealthcare Gamma Fund (USD) L.P.Adventure 03 LimitedDinova Venture PartnersGP III, L.P.Dinova Healthcare Gamma Fund (USD) L.P.Dinova Capital LimitedDinova Venture Partners GP III, L.P.Xin Nuo Tong Investment LimitedDinovaCapital LimitedXin Nuo Tong Investment LimitedAdventure 03 Limited •Dinova Venture Partners GP III, L.P.238,112HDinova Capital LimitedDinovaVenture Partners GP III, L.P.Xin Nuo Tong Investment LimitedDinova CapitalLimitedXin Nuo Tong Investment LimitedDinova Venture Partners GP III, L.P. •6,977,955H40% •DNA 01Hong Kong Limited919,805HDinovaHealthcare Delta Fund (USD) L.P.DNA 01Hong Kong LimitedDinova VenturePartners GP IV, L.P.Dinova Healthcare Delta Fund (USD) L.P.Dinova Venture CapitalLimitedDinova Venture Partners GP IV, L.P.Xin Nuo Tong Investment LimitedDinova Venture Capital Limited 40%Xin Nuo Tong Investment LimitedDNA 01Hong Kong Limited •1,687,358H66.67% •269,678H •1,208Jupiter Holdings LimitedMercury HoldingLimited (3)Qiming Corporate GP III, Ltd.57,048,980H •Ming Zhi Investments (BVI) Limited40,018,283HMing Zhi Investments LimitedMing Zhi Investments (BVI) LimitedQiming Venture Partners III, L.P.Ming Zhi Investments Limited 96.94%Qiming GP III, L.P.Qiming Venture Partners III, L.P.Ming ZhiInvestments (BVI) Limited